Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
2.310
+0.050 (2.21%)
At close: Aug 5, 2025, 4:00 PM
2.280
-0.030 (-1.28%)
After-hours: Aug 5, 2025, 7:54 PM EDT
Humacyte Employees
As of December 31, 2024, Humacyte had 220 total employees, including 218 full-time and 2 part-time employees. The number of employees increased by 35 or 18.92% compared to the previous year.
Employees
220
Change (1Y)
35
Growth (1Y)
18.92%
Revenue / Employee
$2,350
Profits / Employee
-$363,818
Market Cap
358.32M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 220 | 35 | 18.92% |
| Dec 31, 2023 | 185 | 21 | 12.80% |
| Dec 31, 2022 | 164 | 18 | 12.33% |
| Dec 31, 2021 | 146 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
HUMA News
- 13 days ago - Humacyte Announces First Symvess™ Sale to Military Treatment Facility - GlobeNewsWire
- 4 weeks ago - Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency - GlobeNewsWire
- 7 weeks ago - Humacyte: Revenue Ramp From Symvess Incoming - Seeking Alpha
- 2 months ago - Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting - GlobeNewsWire
- 2 months ago - Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3 - GlobeNewsWire
- 2 months ago - Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq - GlobeNewsWire
- 3 months ago - Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire